Equities

Skye Bioscience Inc

SKYE:NMQ

Skye Bioscience Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.17
  • Today's Change-0.11 / -2.57%
  • Shares traded100.88k
  • 1 Year change+159.01%
  • Beta1.7400
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system. The Company's clinical assets focus on the modulation of cannabinoid receptor 1 (CB1) to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. Its Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion (SBI-100 OE), a CB1 agonist (activator), being developed for the treatment of glaucoma and ocular hypertension. The Company's Phase 2 study in obesity is designed to evaluate nimacimab's weight loss potential either as a single agent or in combination with a glucagon-like peptide-1 (GLP-1) agonist like semaglutide.

  • Revenue in USD (TTM)0.00
  • Net income in USD-21.24m
  • Incorporated2011
  • Employees11.00
  • Location
    Skye Bioscience Inc11250 EL CAMINO REAL, SUITE 100SAN DIEGO 92130United StatesUSA
  • Phone+1 (858) 410-0266
  • Fax+1 (775) 782-2611
  • Websitehttps://skyebioscience.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Outlook Therapeutics Inc0.00-94.05m121.35m24.00---------8.12-8.120.00-3.570.00----0.00-205.48-214.69---1,843.48-------3,043.92---26.89--------10.70------
Ventyx Biosciences Inc0.00-152.52m122.33m75.00--0.4386-----2.37-2.370.003.940.00----0.00-48.98---52.21--------------0.00-------77.97------
Vigil Neuroscience Inc0.00-82.60m122.64m66.00--1.34-----2.07-2.070.002.230.00----0.00-56.88---66.15--------------0.00-------20.98------
Cidara Therapeutics Inc18.86m-123.53m122.96m69.00--1.06--6.52-26.06-25.943.7416.410.167--8.28273,304.30-109.42-65.23-169.41-154.3787.21---655.07-100.61----0.0055---0.8425--31.72--23.33--
Seres Therapeutics Inc64.00k-165.29m124.55m233.00--5.21--1,946.13-1.14-0.22710.00040.14050.0002----274.68-60.50-41.51-82.15-54.13-----258,259.40-170.14---20.450.00--1,672.2434.9154.54--32.72--
Pyxis Oncology Inc16.15m-57.36m124.88m54.00--0.8124--7.73-1.05-1.050.29772.590.0845----322,920.00-30.03---34.41--97.06---355.24------0.0008------38.87------
Repare Therapeutics Inc66.52m-84.05m126.26m179.00--0.7216--1.90-2.00-2.001.564.120.270--3.95371,642.50-34.11-23.40-40.73-26.37-----126.34-162.76----0.00---61.21---222.91--27.16--
Skye Bioscience Inc0.00-21.24m126.51m11.00--1.67-----0.8405-0.84050.002.500.00----0.00-43.73-232.67-54.60--------------0.00-------93.23--23.38--
Coherus Biosciences Inc304.34m-450.00k126.73m235.00----26.100.4164-0.0892-0.08922.60-0.76360.55912.941.58994,575.20-0.0827-21.43-0.1626-29.3244.7179.01-0.1479-36.561.09-3.921.50--21.89--18.46---18.37--
Cardiff Oncology Inc689.00k-43.01m127.83m31.00--2.47--185.54-0.9493-0.94930.01521.010.0091--1.6922,225.81-56.80-31.24-66.22-33.56-----6,238.17-7,819.23----0.00--26.425.22-7.07--157.91--
Fennec Pharmaceuticals Inc49.35m-1.13m129.48m36.00------2.62-0.1004-0.10041.75-0.18861.272.225.66---2.91-73.43-3.40-84.3293.52---2.30-383.287.640.59781.21--1,284.50--32.34------
TriSalus Life Sciences Inc26.89m-58.65m129.85m112.00------4.83-1.68-1.680.8963-0.67060.88121.236.75240,098.20-181.70---265.24--87.10---206.19--2.00-26.4317.43--49.31---26.51------
Data as of Nov 21 2024. Currency figures normalised to Skye Bioscience Inc's reporting currency: US Dollar USD

Institutional shareholders

32.93%Per cent of shares held by top holders
HolderShares% Held
Sphera Funds Management Ltd.as of 30 Sep 20241.56m5.15%
Baker Bros. Advisors LPas of 30 Sep 20241.43m4.73%
Altium Capital Management LPas of 30 Sep 20241.32m4.34%
BlackRock Fund Advisorsas of 30 Sep 20241.10m3.64%
Schonfeld Strategic Advisors LLCas of 30 Sep 2024959.10k3.16%
Ensign Peak Advisors, Inc.as of 30 Sep 2024900.00k2.97%
The Vanguard Group, Inc.as of 30 Sep 2024828.82k2.73%
Heights Capital Management, Inc.as of 30 Jun 2024679.74k2.24%
Driehaus Capital Management LLCas of 30 Sep 2024650.76k2.15%
Alyeska Investment Group LPas of 30 Sep 2024554.18k1.83%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.